• Amphastar Pharmaceuticals, Inc. reported its first-quarter 2026 results on May 7, 2026, with sales of US$171.17 million and net income of US$6.42 million, compared with US$170.53 million and US$25.29 million a year earlier.
• The sharp fall in net income and earnings per share, despite essentially flat sales, points to pressure on Amphastar’s profitability and cost structure.
• With Amphastar’s net income falling year over year despite stable sales, we’ll now examine how this affects the company’s existing investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Amphastar Pharmaceuticals Investment Narrative Recap

To own Amphastar, you need to believe the company can turn its mix of generics, proprietary drugs, and BAQSIMI into consistent, defendable profits. The latest quarter challenges that view in the near term: net income dropped sharply to US$6.42 million while sales were flat at about US$171 million, keeping pressure on margins. That makes Amphastar’s ability to stabilize profitability the key short term catalyst, with further earnings erosion the most immediate risk.

In this context, Amphastar’s plan to present at the Bank of America Health Care Conference on May 13, 2026, takes on added importance. Management will have an opportunity to explain what is driving weaker margins, how BAQSIMI and the broader pipeline fit into the path forward, and whether recent cost trends are temporary or more structural, which could meaningfully shape how investors view both the current pressure and the longer term investment case.

Yet behind the recent headline numbers, one risk in particular is becoming more important for investors to keep an eye on...

Amphastar Pharmaceuticals' narrative projects $824.2 million revenue and $109.0 million earnings by 2029.

Uncover how Amphastar Pharmaceuticals' forecasts yield a $28.00 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts expected Amphastar’s revenue to reach about US$865.5 million and earnings about US$109.8 million by 2029, so if you worry about rising R&D costs outpacing new product sales, this latest profit drop might make you question how comfortably those targets can be met or whether the story needs to be updated.

Explore 3 other fair value estimates on Amphastar Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amphastar Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Amphastar Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amphastar Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.